Volume | 833,346 |
|
|||||
News | - | ||||||
Day High | 1.59 | Low High |
|||||
Day Low | 1.52 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Lexicon Pharmaceuticals Inc | LXRX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.59 | 1.52 | 1.59 | 1.60 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
2,104 | 833,346 | $ 1.54 | $ 1,283,551 | - | 0.92 - 3.789 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
12:34:07 | 65 | $ 1.555 | USD |
Lexicon Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
377.18M | 244.92M | - | 1.2M | -177.12M | -0.72 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Lexicon Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LXRX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.67 | 1.8575 | 1.52 | 1.65 | 3,220,915 | -0.12 | -7.19% |
1 Month | 2.18 | 2.47 | 1.52 | 1.91 | 3,054,458 | -0.63 | -28.90% |
3 Months | 1.95 | 3.73 | 1.52 | 2.46 | 4,691,594 | -0.40 | -20.51% |
6 Months | 1.17 | 3.73 | 0.92 | 2.04 | 3,612,021 | 0.38 | 32.48% |
1 Year | 2.36 | 3.789 | 0.92 | 2.05 | 2,972,717 | -0.81 | -34.32% |
3 Years | 4.97 | 6.3299 | 0.92 | 2.48 | 1,508,641 | -3.42 | -68.81% |
5 Years | 5.72 | 9.65 | 0.92 | 3.23 | 1,912,831 | -4.17 | -72.90% |
Lexicon Pharmaceuticals Description
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes. |